supplementary data - dove medical press€¦ · web viewsupplementary data design and...
TRANSCRIPT
Supplementary data
Design and characterisation of novel sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma
Mahmoud M.A. El-Sayed1, Mahmoud E. Mostafa2, Eman Alaaeldin2,3, Hatem
A. A. Sarhan2, Montaser Sh. A. Shaykoon4, Shady Allam5, Ahmed R.H.
Ahmed6, and Bakheet E. M. Elsadek7,*
1Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy,
Sohag University, Egypt2Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Egypt3Department of Clinical Pharmacy, Deraya University, Minia, Egypt4Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar
University, Assiut Branch, Egypt5Department of Pharmacology and Toxicology, Faculty of
Pharmacy, Kafrelsheikh University, Egypt6Department of Pathology, Faculty of Medicine, Sohag University, Egypt7Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Al-
Azhar University, Assiut Branch, Egypt
*Corresponding author: To whom correspondence should be addressed:
Dr. Bakheet E. M. Elsadek, Associate Professor of Biochemistry and
Molecular Biology, Faculty of Pharmacy, Al–Azhar University, Assiut Branch,
P. O. Box 71524, Assiut, Egypt. E–mail: [email protected]; Tel.:
+201110596270
ORCID: 0000-0001-5444-0245
Keywords: Carbon nanotubes, Sorafenib, DENA, Hepatocellular carcinoma,
Microcapsules
1
Zeta potential estimations
Figure 1S. Zeta potential of (A) Pristine CNTs, (B) CNTs-COOH, (C) CNTs-
COCl, (D) CNTs-PEG (E) CNTs-SFN
2
DSC spectroscopy
Figure 2Sa: DSC thermogram of Calcium Chloride
Figure 2Sb: DSC thermogram of, Sodium Alginate
3
Figure 2Sc: DSC thermogram of, Sorafenib tosylate
Figure 2Sd: DSC thermogram of plain microcapsules
4
Figure 2Se: DSC thermogram of MWCNTs-SFN Microencapsulation.
5
Figure 3S: SEM images of the drug-loaded microcapsules after a three
months storage period at 25°C (A), 30°C (B), and 40°C (C) in a RH of
75±5%, at different magnification powers.
6
Morphological changes in the liver features
Figure 4S: Representative photographs of livers from the control group (A1–
5); DENA group (B1–4); SFN group (C1–4); and CNTs-SFN-MCs group
(D1–5) group.
7
Western blot results
Figure 5S: Representative western blot analysis of GP73 (A1-2), GPC-3 (B1-2) and HSP70 (C1-2) expressions in liver tissues of different groups.
8
Immunofluorescence staining
Figure 6S: Representative illustration of liver tissue sections immunofluorescence stained for detection of CTGF, FGF-2, HIF-1α, and mTOR as HCC-relevant biomarkers in untreated control (A), DENA (B), DENA/SFN (C), and DENA/CNTs-SFN-MCs (D) groups.
9
Figure 7S: Representative illustration of liver tissue sections immunofluorescence stained for detection of CTGF, FGF-2, HIF-1α, and mTOR as HCC-relevant biomarkers in untreated control (A), DENA (B), DENA/SFN (C), and DENA/CNTs-SFN-MCs (D) groups.
10
Histopathological examinations
Figure 8S: Sections of liver tissue obtained from untreated control rats (A), DENA treated rats (B), DENA/SFN treated rats (C) and DENA/ CNTs-SFN-MCs-treated rats (D). Magnification power is x10.
11
Figure 9S: Sections of liver tissue obtained from untreated control rats (A), DENA treated rats (B), DENA/SFN treated rats (C) and DENA/CNTs-SFN-MCs-treated rats (D). Magnification power is x20.
12